Pediatric Infection and Vaccine

The Korean Society of Pediatric Infectious Diseases (대한소아감염학회)
권호 표지
DOI QR코드

DOI QR Code

A Retrospective Analysis of Characteristics of Probiotics Associated with Invasive Bacterial Infections in Children

소아청소년에서 발생한 유산균 제제에 포함된 균주에 의한 침습성 감염증의 후향적 분석

  • Koh, June Young (Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine) ;
  • Seo, Euri (Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine) ;
  • Lee, Jina (Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine)
  • 고준영 (울산대학교 의과대학 서울아산병원 어린이병원 소아청소년과) ;
  • 서유리 (울산대학교 의과대학 서울아산병원 어린이병원 소아청소년과) ;
  • 이진아 (울산대학교 의과대학 서울아산병원 어린이병원 소아청소년과)
  • Received : 2017.08.16
  • Accepted : 2017.10.13
  • Published : 2017.12.25
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The purpose of this study was to analyze the clinical features and risk factors of invasive infections caused by Lactobacillus spp. and Saccharomyces spp., components of commercially available probiotics. Methods: We analyzed demographic and clinical data from children ${\leq}18$ years of age with an invasive infection caused by Lactobacillus spp. or Saccharomyces spp. at the Asan Medical Center Children's Hospital from January 1998 to June 2016. Probiotic consumption data were also analyzed. Results: During the study period, a total of 24 episodes of invasive infections were caused by Lactobacillus spp. (n=16) and Saccharomyces cerevisiae (n=8). Along with the increase of probiotic use (755,594 [days/1,000 patient-admission days] in 2001 to 2005, 1,444,066 in 2006 to 2010, and 6,904,736 in 2011 to 2016), the incidence of probiotic-associated invasive infection increased ($R^2=0.70$). The median age of the patients was 1.8 years (range, 2 months to 17 years), and most of them had underlying medical conditions. The 30-day mortality rate was 20.8% (5/24), and 11 (45.8%) of these patients resulted from a severe invasive infection. We determined the risk factors for invasive infection to be: previous intensive care unit stay (odds ratio [OR], 3.0; 95% confidence interval [CI], 1.5 to 6.1] and the presence of a central venous catheter (OR, 2.2; 95% CI, 1.2 to 4.3). Conclusions: Although the probiotic-associated invasive infections rarely occurred in children, the incidence has increased along with probiotic pressure. Judicious use of probiotics is mandatory, especially in young children with underlying medical conditions and continuous surveillance will be needed to minimize the safety concerns.

목적: 국내 소아에서 발생한 유산균 제제 내 포함 균주(Lactobacillus spp. 및 Saccharomyces spp.)에 의한 침습적 감염증의 임상 경과를 기술하고 중증 감염증 발생과 관련된 인자들을 분석하였다. 방법: 1998년 1월부터 2016년 6월까지 서울아산병원 어린이병원에서 18세 이하의 소아청소년 환아에게서 발생한 Lactobacillus spp. 및 Saccharomyces spp.에 의한 침습적 감염증의 의무기록과 2001년 1월부터 2016년 6월까지 원내에서 처방된 유산균 제제 처방량 자료를 후향적으로 분석하였다. 결과: 연구 기간 동안 총 24명의 침습적 감염이 발생하였다(Lactobacillus spp. 16예 및 Saccharomyces spp. 8예). 유산균 제제의 처방량은 2001년부터 2016년까지 통계적으로 유의미하게 증가하는 양상을 보였으며, 이에 따라 침습적 감염증의 발생률도 증가하였다($R^2=0.70$). 환아들의 중간 연령은 1.8세(범위, 2개월-17세)이었고, 1명을 제외한 환아에서 기저질환을 동반하였다. 30일 사망률은 20.8% (5/24)였으며, 중증 감염증은 11예(45.8%)에서 발생하였다. 어린 연령의 환아이거나(P=0.02), 선천 심질환이 있는 경우(P=0.01) 또는 침습적 감염증 발생 전 중환자실 재실 중이었거나(odds ratio [OR], 3.0; 95% confidence interval [CI], 1.5-6.1), 중심정맥관을 가지고 있던 경우(OR, 2.2; 95% CI, 1.2-4.3)에 통계적으로 유의미하게 중증 감염으로의 발현이 증가하였다. 결론: 소아에서의 유산균 제제 내 균주에 의한 감염증은 흔하게 발생하지는 않지만, 유산균 제제의 사용량 증가와 함께 증가하는 양상을 보였다. 어린 환아 및 기저질환을 가지고 있거나 중환자실 치료 또는 중심정맥관을 보유하고 있는 환아에 대해서는 안전성을 고려하여 유산균 제제의 사용에 주의를 기울여야 한다.

Keywords

References

  1. Araya M, Morelli L, Reid G, Sanders ME, Stanton C. Guidelines for the evaluation of probiotics in food: report of a joint FAO/WHO working group on drafting guidelines for the evaluation of probiotics in food 2002 [Internet]. Geneva: World Health Orgarnization; 2017 [cited 2017 Nov 18]. Available from: http://www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf.
  2. Lherm T, Monet C, Nougiere B, Soulier M, Larbi D, Le Gall C, et al. Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med 2002;28:797-801. https://doi.org/10.1007/s00134-002-1267-9
  3. Cassone M, Serra P, Mondello F, Girolamo A, Scafetti S, Pistella E, et al. Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism. J Clin Microbiol 2003;41:5340-3. https://doi.org/10.1128/JCM.41.11.5340-5343.2003
  4. Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM. Lactobacillus endocarditis caused by a probiotic organism. Clin Microbiol Infect 1999;5:290-2. https://doi.org/10.1111/j.1469-0691.1999.tb00144.x
  5. Rautio M, Jousimies-Somer H, Kauma H, Pietarinen I, Saxelin M, Tynkkynen S, et al. Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 1999;28:1159-60. https://doi.org/10.1086/514766
  6. Hempel S, Newberry S, Ruelaz A, Wang Z, Miles JN, Suttorp MJ, et al. Safety of probiotics used to reduce risk and prevent or treat disease. Evid Rep Technol Assess (Full Rep) 2011;(200):1-645.
  7. Wallace TC, MacKay D. The safety of probiotics: considerations following the 2011 U.S. Agency for Health Research and Quality report. J Nutr 2011;141:1923-4. https://doi.org/10.3945/jn.111.147629
  8. Mitterdorfer G, Mayer HK, Kneifel W, Viernstein H. Protein fingerprinting of Saccharomyces isolates with therapeutic relevance using one- and two-dimensional electrophoresis. Proteomics 2002;2:1532-8. https://doi.org/10.1002/1615-9861(200211)2:11<1532::AID-PROT1532>3.0.CO;2-H
  9. van der Aa Kuhle A, Jespersen L. The taxonomic position of Saccharomyces boulardii as evaluated by sequence analysis of the D1/D2 domain of 26S rDNA, the ITS1-5.8S rDNA-ITS2 region and the mitochondrial cytochromecoxidase II gene. Syst Appl Microbiol 2003;26:564-71. https://doi.org/10.1078/072320203770865873
  10. Center for Disease Control and Prevention/National Healthcare Safety Network. Bloodstream infection event (central line-associated bloodstream infection and noncentral line-associated bloodstream infection) [Internet]. Atlanta: Center for Disease Control and Prevention; 2016 [cited 2017 Nov 17]. Available from: http://www.cdc.gov.
  11. Salminen MK, Tynkkynen S, Rautelin H, Saxelin M, Vaara M, Ruutu P, et al. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis 2002;35:1155-60. https://doi.org/10.1086/342912
  12. Salminen MK, Rautelin H, Tynkkynen S, Poussa T, Saxelin M, Valtonen V, et al. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis 2004;38:62-9. https://doi.org/10.1086/380455
  13. Munoz P, Bouza E, Cuenca-Estrella M, Eiros JM, Perez MJ, Sanchez-Somolinos M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005;40:1625-34. https://doi.org/10.1086/429916
  14. Enache-Angoulvant A, Hennequin C. Invasive Saccharomyces infection: a comprehensive review. Clin Infect Dis 2005;41:1559-68. https://doi.org/10.1086/497832
  15. U.S. Department of Health and Human Services, Food and Drug Administration. Investigational new drug applications (INDs): determining whether human research studies can be conducted without an IND, guidance for clinical investigators [Internet]. Silver Spring: FDA; 2013 [cited 2017 Nov 17]. Available from: https://www.fda.gov/downloads/drugs/guidances/ucm229175.pdf.
  16. Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr 2006; 83:1256-64. https://doi.org/10.1093/ajcn/83.6.1256
  17. Hennequin C, Kauffmann-Lacroix C, Jobert A, Viard JP, Ricour C, Jacquemin JL, et al. Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis 2000;19:16-20. https://doi.org/10.1007/s100960050003
  18. Atici S, Soysal A, Karadeniz Cerit K, Yilmaz S, Aksu B, Kiyan G, et al. Catheter-related Saccharomyces cerevisiae fungemia following Saccharomyces boulardii probiotic treatment: in a child in intensive care unit and review of the literature. Med Mycol Case Rep 2017;15:33-5. https://doi.org/10.1016/j.mmcr.2017.02.002
  19. Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C. Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis. J Clin Microbiol 1998;36:325-6.
  20. Bassetti S, Frei R, Zimmerli W. Fungemia with Saccharomyces cerevisiae after treatment with Saccharomyces boulardii. Am J Med 1998;105:71-2. https://doi.org/10.1016/S0002-9343(98)00133-8

Cited by

  1. Targeting Risk Factors for the Control of Central Line-Associated Bloodstream Infection in the Neonatal Intensive Care Unit: A Single Tertiary Center Experience vol.28, pp.3, 2017, https://doi.org/10.5385/nm.2021.28.3.116